Colistin presentations
Population pharmacokinetics of colistin methanesulfonate (CMS) and colistin in critically ill patients receiving intermittent haemodialysis
N. Grégoire, B. Mégarbane, E. Comets, P. Gobin, D. Balayn, O. Mimoz, W. Couet (Poitiers, Paris, FR). ECCMID 2013, 30 April 2013,Abstract (oral session): Old drugs, new challenges - PK/PD for glycopeptides and polymyxins
Whole-body physiologically-based pharmacokinetic model for colistin and colistimethate sodium (CMS) in five different animal species: mouse, rat, rabbit, baboon and pig
S. Bouchene*, S. Marchand, L.E. Friberg, S. Björkman, W. Couet, M.O. Karlsson (Uppsala, SE; Poitiers, FR). ECCMIDl 2013, Abstract (poster session), PK/PD: new drugs, the critically and resistant bugsNephrotoxicity of colistin and role of kidney disease on patient outcomes in infections due to extensively-drug resistant Acinetobacter baumannii
R. Andini, E. Durante Mangoni*, A. Senese, D. Pinto, F. Agrusta, I. Mattucci, V. Farinaro, C. Graziano, C. Battimelli, C. Savinelli, V. Iorio, M. Bassetti, P. Malacarne, N. Petrosillo, C. Viscoli, R. Utili (Naples, Genoa, Pisa, Rome, IT). ECCMID 2013, Abstract (oral session),Old drugs, new challenges - PK/PD for glycopeptides and polymyxins
Comparison of colistin-carbapenem, colistin-sulbactam and colistin-other antibacterial agent for treatment of multidrug-resistant Acinetobacter bacteraemia: a multicentre retrospective study
A. Batirel, I.I. Balkan, O. Karabay, C. Agalar, S. Akalin, O. Alici, F.A. Altay, N. Altin, F. Arslan, T. Aslan, N. Bekiroglu, S. Cesur, A.D. Celik, M. Dogan, B. Durdu, F. Duygu, A. Engin, D.O. Engin, I. Gonen, E. Guclu, T. Guven, C.A. Hatipoglu, S. Hosoglu, M.K. Karahocagil, A. Ulu Kilic, E. Alp Mese, B. Ormen, D. Ozdemir, S. Ozer, N. Oztoprak, N. Sezak, V. Turhan, N. Turker, H. Yilmaz (Istanbul, Sakarya, Denizli, Ankara, Edirne, Tekirdag, Tokat, Sivas, Isparta, Diyarbakir, Van, Kayseri, Izmir, Duzce, Antalya, Samsun, TR). ECCMID 2013, Abstract (oral session), Evolving therapeutic strategies for serious infectionsMonotherapy versus combination treatment against multidrug-resistant (MDR) Acinetobacter baumannii infection. Study GEIH/REIPI-Ab 2010
L.E. López-Cortés*, J. Rodríguez-Baño, A. Pascual, G. Bou Arevalo, M. Tomás-Carmona, J. Garnacho, F. Fernández-Cuenca, L. Martínez-Martínez, J. Vila, J. Pachón, J.M. Cisneros on behalf of the GEIH-REIPI-Ab 2010 working group. ECCMID 2013, Abstract (oral session),Evolving therapeutic strategies for serious infections